Emcure Pharma Share Price Target 2026, 2027, 2030, 2040, 2050
Emcure Pharmaceuticals is an Indian medicine company that makes good-quality, affordable medicines for many long-term health problems like heart issues, cancer, diabetes, HIV, and women’s health. The company makes many types of medicines, such as tablets, syrups, injections, special drug ingredients (APIs), and advanced biologic medicines, and sells them in India and in more than 70 countries. It has 13 factories and 5 research centres in India, where it works on new ideas to make better treatments.
What is Emcure Pharmaceuticals Ltd NSE: EMCURE?
Emcure Pharmaceuticals was established in 1981 in Pune by Satish Mehta. It is an Indian medicine company that makes and sells many kinds of medicines in India and in over 70 countries. The company makes medicines for women’s health, heart problems, cancer, HIV, infections, diabetes, and many other health issues. It produces tablets, capsules, injections, biologics, and other advanced medicines in its many factories across India. It has slowly grown from a small company into a major international pharma brand with strong research, modern technology, and a growing global presence.
It works in many important health areas such as women’s health, heart problems, blood disorders, cancer, diabetes, HIV, vitamins, and infection control. It makes many types of medicines like tablets, syrups, injections, biologics, and complex APIs. Because of this wide range, doctors have many choices to treat different health issues. This also helps it serve many kinds of patients, from those with simple problems to those with serious or long-term diseases. In 2026, its share price target would be ₹2407, as per stock market analysts.
According to stock market analysts, its share price would be between ₹1356 to ₹2407 in 2026.
| वर्ष | न्यूनतम मूल्य (Rs) | अधिकतम मूल्य (Rs) |
| 2026 | 1356 | 2407 |
| महीना | न्यूनतम मूल्य (Rs) | अधिकतम मूल्य (Rs) |
| जनवरी | 1356 | 1585 |
| फ़रवरी | 1386 | 1565 |
| मार्च | 1381 | 1671 |
| अप्रैल | 1400 | 1771 |
| मई | 1442 | 1835 |
| जून | 1525 | 1900 |
| जुलाई | 1645 | 1953 |
| अगस्त | 1781 | 2000 |
| सितंबर | 1800 | 2140 |
| अक्टूबर | 1855 | 2257 |
| नवंबर | 1890 | 2378 |
| दिसम्बर | 1966 | 2407 |
This company has 13 manufacturing plants and 5 research centres in India. These centres help the company make new medicines, test new ideas, and produce drugs in large quantities. It ensures its medicines are safe and reliable with modern machines, skilled scientists, and strict quality checks. This strong setup helps the company make everything from simple tablets to advanced biologics. Having all these facilities also helps Emcure stay competitive and continue improving. In 2027, its share price target would be ₹3181, as per stock market analysts.
According to stock market analysts, its share price would be between ₹2625 to ₹3181 in 2027.
| वर्ष | न्यूनतम मूल्य (Rs) | अधिकतम मूल्य (Rs) |
| 2027 | 2625 | 3181 |
In the beginning, it mostly made medicines for other big international pharma companies. But later, it changed its direction and started making its own products. This helped the company build its own brand, develop strong research abilities, and control everything from production to marketing. This change helped the company grow into a respected and independent pharmaceutical leader, trusted by doctors and patients. In 2028, its share price target would be ₹3700, as per stock market analysts.
According to stock market analysts, its share price would be between ₹3142 to ₹3700 in 2028.
| वर्ष | न्यूनतम मूल्य (Rs) | अधिकतम मूल्य (Rs) |
| 2028 | 3142 | 3700 |
It is known for making advanced medicines like biologics, complex APIs, and special formulations. These kinds of products need high skills, advanced technology, and strong scientific knowledge. By investing in these areas, Emcure entered the field of speciality medicines, which includes treatments for cancer, rare diseases, and serious infections. This gives the company an advantage over companies that only make basic, generic medicines. In 2029, its share price target would be ₹4168, as per stock market analysts.
According to stock market analysts, its share price would be between ₹3652 to ₹4168 in 2029.
| वर्ष | न्यूनतम मूल्य (Rs) | अधिकतम मूल्य (Rs) |
| 2029 | 3652 | 4168 |
In India, it is a leader in women’s health and HIV treatment. Doctors trust the company because it has been making reliable medicines for many years. Its strong presence in different therapy areas helps it stay stable even when the demand for some medicines goes up or down. Its leadership shows the company’s quality, value, and long-term trust among healthcare professionals. In 2030, its share price target would be ₹4955, as per stock market analysts.
According to stock market analysts, its share price would be between ₹4120 to ₹4955 in 2030.
| वर्ष | न्यूनतम मूल्य (Rs) | अधिकतम मूल्य (Rs) |
| 2030 | 4120 | 4955 |
| महीना | न्यूनतम मूल्य (Rs) | अधिकतम मूल्य (Rs) |
| जनवरी | 4120 | 4332 |
| फ़रवरी | 4174 | 4384 |
| मार्च | 4211 | 4420 |
| अप्रैल | 4250 | 4478 |
| मई | 4278 | 4512 |
| जून | 4332 | 4580 |
| जुलाई | 4357 | 4635 |
| अगस्त | 4384 | 4675 |
| सितंबर | 4425 | 4758 |
| अक्टूबर | 4525 | 4790 |
| नवंबर | 4575 | 4825 |
| दिसम्बर | 4678 | 4955 |
It is also known for bringing new and advanced medicines to the Indian market. It has launched many first-of-their-kind products, including special iron medicines, biologics, and improved formulations. This focus on new ideas helps it to stand out from companies that only make regular, generic drugs. It supports patients who need better and more effective treatment options by offering unique medicines early. In 2040, its share price target would be ₹9567, as per stock market analysts.
According to stock market analysts, its share price would be between ₹8401 to ₹9567 in 2040.
| वर्ष | न्यूनतम मूल्य (Rs) | अधिकतम मूल्य (Rs) |
| 2040 | 8401 | 9567 |
| महीना | न्यूनतम मूल्य (Rs) | अधिकतम मूल्य (Rs) |
| जनवरी | 8401 | 8620 |
| फ़रवरी | 8451 | 8668 |
| मार्च | 8474 | 8689 |
| अप्रैल | 8535 | 8720 |
| मई | 8589 | 8742 |
| जून | 8635 | 8832 |
| जुलाई | 8675 | 8874 |
| अगस्त | 8745 | 8961 |
| सितंबर | 8820 | 9154 |
| अक्टूबर | 8936 | 9256 |
| नवंबर | 9057 | 9384 |
| दिसम्बर | 9224 | 9567 |
It works with many international partners to develop, make, and sell medicines around the world. These partnerships help the company get new technologies, better production methods, and new ideas for treatments. Through such collaborations, it is able to offer advanced therapies at affordable prices in developing countries. These global partnerships also strengthen its presence and build long-lasting trust. In 2050, its share price target would be ₹14000, as per stock market analysts.
According to stock market analysts, its share price would be between ₹12900 to ₹14000 in 2050.
| वर्ष | न्यूनतम मूल्य (Rs) | अधिकतम मूल्य (Rs) |
| 2050 | 12900 | 14000 |
| महीना | न्यूनतम मूल्य (Rs) | अधिकतम मूल्य (Rs) |
| जनवरी | 12900 | 13204 |
| फ़रवरी | 13010 | 13357 |
| मार्च | 13077 | 13384 |
| अप्रैल | 13175 | 13458 |
| मई | 13235 | 13562 |
| जून | 13275 | 13663 |
| जुलाई | 13368 | 13690 |
| अगस्त | 13458 | 13744 |
| सितंबर | 13558 | 13780 |
| अक्टूबर | 13622 | 13853 |
| नवंबर | 13715 | 13921 |
| दिसम्बर | 13852 | 14000 |
Should I buy Emcure Pharma stock?
| वर्ष | न्यूनतम मूल्य (Rs) | अधिकतम मूल्य (Rs) |
| 2026 | 1356 | 2214 |
| 2027 | 2625 | 3181 |
| 2028 | 3142 | 3700 |
| 2029 | 3652 | 4168 |
| 2030 | 4120 | 4955 |
| 2040 | 8401 | 9567 |
| 2050 | 12900 | 14000 |
It could be a good choice for people who want to invest for the medium or long term because the company is growing well, earning more revenue and profit, and selling medicines in India and other countries. But the stock can go up and down, and there are risks like competition and government rules. So, it may be suitable for investors who are okay with some ups and downs and believe the company will grow over time. People who want very safe or short-term investments should be careful.
Emcure Pharma earnings results
| मार्च 2020 | मार्च 2021 | मार्च 2022 | मार्च 2023 | मार्च 2024 | मार्च 2025 | टीटीएम | |
| बिक्री + | 5,049 | 5,033 | 5,855 | 5,986 | 6,658 | 7,896 | 8,449 |
| व्यय + | 4,340 | 3,817 | 4,525 | 4,804 | 5,429 | 6,427 | 6,793 |
| परिचालन लाभ | 708 | 1,216 | 1,330 | 1,182 | 1,230 | 1,469 | 1,656 |
| OPM % | 14% | 24% | 23% | 20% | 18% | 19% | 20% |
| अन्य आय + | -25 | -159 | 63 | 39 | 47 | 62 | -6 |
| ब्याज | 257 | 155 | 176 | 214 | 237 | 176 | 130 |
| व्याख्या | 321 | 250 | 245 | 260 | 312 | 384 | 398 |
| कर से पहले लाभ | 105 | 652 | 973 | 747 | 727 | 971 | 1,123 |
| कर | 4% | 36% | 28% | 25% | 27% | 27% | |
| नेट प्रॉफिट + | 101 | 419 | 703 | 562 | 528 | 707 | 819 |
| रुपये में ईपीएस | 4.62 | 23.15 | 36.62 | 29.42 | 27.50 | 35.96 | 41.84 |
| लाभांश भुगतान % | 54% | 4% | 8% | 7% | 7% | 8% |
कुंजी मीट्रिक
| TTM PE Ratio | PB अनुपात | लाभांश प्राप्ति | सेक्टर PE | सेक्टर PB | सेक्टर Div Yld |
| 33.37 | 5.70 | 0.21% | 36.87 | 5.82 | 0.59% |
Peers & तुलना
| स्टॉक | पीई अनुपात | PB अनुपात | लाभांश प्राप्ति |
| Emcure Pharmaceuticals Ltd | 38.85 | 5.70 | 0.21% |
| Sun Pharmaceutical Industries Ltd | 39.63 | 5.98 | 0.89% |
| Torrent Pharmaceuticals Ltd | 67.04 | 16.88 | 0.85% |
| Cipla Ltd | 23.30 | 3.93 | 1.05% |
Is Emcure Pharma stock good to buy? (bull case & bear case)
बुल केस:
- In Q4 FY25, its revenue rose about 19.5% compared to last year, reaching ₹2,116 crore.
- Profit after tax (PAT) in Q4 FY25 increased aby bout 63% from last year, reaching around ₹197 crore.
- EBITDA in Q4 FY25 grew about 25% year-on-year, and the EBITDA margin improved to around 18.4–19.0%, showing better efficiency.
- For the full year FY25, total revenue was about ₹7,896 crore, up from ₹6,658 crore in FY24 (18.6% growth), and PAT was about ₹707 crore, up from ₹528 crore in FY24 (34% rise).
- Revenue growth comes from both domestic business (around ₹929 crore in Q4 FY25) and international business (around ₹1,187 crore), showing the company earns from multiple sources.
भालू का मामला:
- Comparing quarter to quarter, Q3 FY25 revenue was about ₹1,962 crore, and net profit was about ₹153.7 crore, which shows some ups and downs in performance.
- Gross profit margin in Q4 FY25 was about 57.8%, down from 62.1% last year, meaning the costs of making medicines are rising.
- The pharma industry has strong competition, pricing pressure, and strict rules, which can reduce profits.
- To keep growing, the company must keep launching new medicines, maintain demand in India and abroad, and control costs — any slip-ups could affect results.
निष्कर्ष
It is an Indian medicine company. It makes many types of affordable and good-quality medicines for health problems like heart disease, cancer, diabetes, HIV, and women’s health. The company has several factories and research centres where it makes tablets, syrups, injections, biologics, and other medicines, and sells them in India and many other countries. It has grown steadily over the years and is known for new ideas, strong research, and its presence worldwide. Its stock may be good for long-term investors, but it has risks like competition, rules, and market changes.
